Celltech, Abgenix in SLAM deal

Celltech (LSE:CCH; CLL) received rights to use ABGX's SLAM (Selected Lymphocyte Antibody

Read the full 122 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE